
If approved, Darzalex would be the first therapy approved in the EU for SMM

The reference medicine holds approvals for multiple HER2-positive breast cancer indications

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

There is currently only one treatment authorised for the ultra-rare genetic blistering disease

Approximately 480,000 cases of the mosquito-borne viral disease were reported globally in 2024

The muscle-wasting disorder is estimated to affect one in every 5,000 male births worldwide

The severe neuromuscular disease affects approximately 2,500 people in the UK

The rare liver disease affects approximately 15 per 100,000 people in Europe

Approximately 121,000 people are diagnosed with primary advanced or recurrent endometrial cancer each year in Europe

Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

The new UK-wide arrangements for medicines will come into effect on 1 January 2025

The neurodegenerative disorder affects an estimated 6.9 million people in Europe